^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Datalai (cetuximab biosimilar)
i
Other names: A140, KL 140, KL-140, A 140, A-140, KL140
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sichuan Kelun Pharma
Drug class:
EGFR antagonist
Related drugs:
3ms
KL140-Ⅲ-02-CTP: Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC (clinicaltrials.gov)
P3, N=688, Completed, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Recruiting --> Completed | Trial completion date: Apr 2023 --> Jan 2024
Trial completion • Trial completion date
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • Datalai (cetuximab biosimilar)
over3years
Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC (clinicaltrials.gov)
P3, N=686, Recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Clinical • New P3 trial
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
BRAF V600E • BRAF V600
|
Erbitux (cetuximab) • oxaliplatin • Datalai (cetuximab biosimilar)
over5years
Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial (clinicaltrials.gov)
P3, N=570, Recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Clinical • New P3 trial
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
oxaliplatin • Datalai (cetuximab biosimilar)
Share via
